Food companies adapt to GLP-1 weight-loss trend
Smaller portions, more protein in response to drug use
Healthy snacks replace meals as snacking trend grows
By Waylon Cunningham and Savyata Mishra
Feb 8 (Reuters) - Pizza, pasta or Chinese take-out used to be the go-to Super Bowl spread for Marla Senzon’s family - until the Florida retiree began taking a GLP-1 appetite-suppressing medication two years ago.
This Sunday, the bowl of choice for Senzon and her husband - who used to take the weight-loss drug - will be a salad, with a light protein like chicken or turkey while they watch the Seattle Seahawks take on the New England Patriots for the U.S. professional football’s NFL championship.
“Everything about our eating habits has changed,” she said. “I can see myself doing it forever.” Changed tense Millions of Americans will watch the Super Bowl on Sunday and with it, commercials that urge them to put down the chicken wings and the loaded nachos. Over the years, weight-loss crazes like the Atkins or paleo diets have swept the nation, only to fizzle out. But as more Americans gain access to cheaper weight-loss medication, food executives are increasingly minding those who are minding their waists.
“We view the GLP-1 trend as somewhat more long-lived and more than just a short-term fad,” Ryan Zink, CEO of Colorado-based Good Times Restaurants (GTIM.O) , which operates more than 60 locations in the United States, told investors on Thursday. The company recently added a protein bowl as a limited-time item that will become part of its core menu in April, he said.
<h3>SMALLER PORTIONS, MORE PROTEIN</h3>
Roughly 12% of Americans are now on one of these drugs, according to analysts at research and brokerage firm Bernstein. For the food companies that produce plenty of highly caloric foods, that means different menu items, smaller portions or different product sizes.
PepsiCo (PEP.O) CEO Ramon Laguarta mentioned GLP-1s for the first time in two years in the company’s earnings call Tuesday. He said the beverage company would try to capitalize on the trends “with a sense of urgency” by selling smaller portions and creating products with more fiber and protein.
The food companies are confronting two trends at once - reduced consumption among weight-loss drug users and consumers frustrated with higher prices. According to the National Restaurant Association’s annual industry report scheduled to be released later in the week, 34% of sit-down restaurant operators said they adjusted portion sizes in 2025 due to rising business costs. The altered appetites of weight-loss drug users may also be a factor, the group’s CEO Michelle Korsmo told Reuters.
“There’s no question GLP-1s are on the mind of restaurant operators,” she said.
<h3>MORE HEALTHY SNACKS</h3>
Upstart drugmaker Hims &amp; Hers (HIMS.N) jolted the industry this week when it announced a compounded version of Novo Nordisk’s Wegovy pill at a $49 introductory price. Just two days later, it backed off the idea under regulatory pressure - but the fanfare stands as a signal that prices for these drugs are likely to keep falling.
GLP-1 users consume roughly 40% fewer calories, which translates to 4% to 6% smaller grocery baskets and 4% to 5% less spending on fast food, said PwC consumer consultant Ali Furman.
The restaurant association says its polling shows 64% of adults are more likely to replace a meal with snack items during the day compared to previous years.
“I don’t think the trend of snacking is going to go backwards. It will shift from unhealthy to more healthy categories,” said Peter Konieczny, chief executive of Switzerland-based packaging company Amcor (AMCR.K) , on Tuesday.
Among global brands, Danone (DANO.PA) North America executives said that GLP-1 adoption is driving demand for high-protein, lower-sugar and digest-supporting foods, such as Greek yogurt. U.S. food giants General Mills (GIS.N) and Conagra Brands (CAG.N) have rolled out high-protein, high-fiber offerings, while meal-kit company HelloFresh introduced GLP-1-friendly recipes in the third quarter of 2025.
“Rising GLP-1 use creates a real opportunity for food companies,” said Zak Stambor, senior analyst in retail and ecommerce at eMarketer. He said many GLP-1 users are willing to spend more than non-users on foods and supplements and even trade up in products like protein shakes “when brands can clearly explain the health benefits.” Restaurant brands are also joining in. Chipotle in December announced a high-protein menu – featuring among other items, a cup of nothing but four ounces of grilled chicken.
Weight-loss drug usage projected to keep rising in coming years
<img src="https://imageproxy.pbkrs.com/https://www.reuters.com/graphics/FOOTBALL-NFL/SUPER%20BOWL-DIET/lgpdqdkrgvo/chart.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1420" height="934" original-src="https://imageproxy.pbkrs.com/https://www.reuters.com/graphics/FOOTBALL-NFL/SUPER%20BOWL-DIET/lgpdqdkrgvo/chart.png"/>

PEPS

GTIM

FTXG

Food companies are adapting to the growing trend of GLP-1 weight-loss medications, which are changing American eating habits. With 12% of Americans on these drugs, companies like Good Times Restaurants and PepsiCo are adjusting their menus to include smaller portions and healthier options. The trend is leading to increased demand for high-protein, low-sugar foods, as consumers shift towards snacking rather than traditional meals. Analysts predict that the use of weight-loss drugs will continue to rise, presenting opportunities for food brands to cater to health-conscious consumers.

Reuters

iShares US Consumer Staples ETF

Parametric Equity Plus ETF

PepsiCo

Invesco Food & Beverage ETF

SPDR FD Consumer Staples

Invesco DB Agriculture FD ETF

VG Consumer Stap

Good Times Restaurants

First Trust NASDAQ Food & Beverage

For many, this year's Super Bowl features a salad - and food companies are racing to react